Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Expert Opinion on Investigational Drugs|June 26, 2023
Safety and pharmacokinetics of IBI112, an IL-23 monoclonal antibody, in Chinese healthy volunteers: a first-in-human phase 1 studyJinjie He, Weijuan Du, Haijing Yang, et al.
Clinical Pharmacology in Drug Development|August 13, 2025
Safety, Tolerability, and Pharmacokinetics of the Long-Acting SARS-CoV-2-Neutralizing Monoclonal Antibody Combination AZD7442 (Tixagevimab/Cilgavimab) in Healthy Chinese AdultsNanyang Li, Jing Zhang, Wenhong Zhang, et al.
Antimicrobial Agents and Chemotherapy|April 22, 2024
Pharmacokinetics and safety of EVER206, a novel polymyxin antimicrobial, in healthy Chinese subjectsSize Li, Xu Zhu, Guoying Cao, et al.
Frontiers in Pharmacology|November 11, 2024
Lefamulin dosing optimization using population pharmacokinetic and pharmacokinetic/pharmacodynamic assessment in Chinese patients with community-acquired bacterial pneumoniaXingchen Bian, Nanyang Li, Yi Li, et al.
Antibiotics (Basel, Switzerland)|April 26, 2024
Age-Related Differences in Vancomycin-Associated Nephrotoxicity and Efficacy in Methicillin-Resistant Staphylococcus aureus Infection: A Comparative Study between Elderly and Adult PatientsLin Xi, Shanshan Li, Mengting Chen, et al.
Frontiers in Pharmacology|June 19, 2023
Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled studyShanshan Li, Xiaojie Wu, Nanyang Li, et al.
Msphere|October 31, 2023
Comparative efficacy of vancomycin in treating ST5 and ST764 methicillin-resistant Staphylococcus aureus infections in adult patientsYaxin Fan, Kaiting Zhang, Mengting Chen, et al.
Antimicrobial Agents and Chemotherapy|May 11, 2021
Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 StudyXiaojie Wu, Nanyang Li, Guoqin Wang, et al.
Pageof 4